Open access
Open access
Powered by Google Translator Translator

Rheumatology

RCT | Effect of Tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy.

22 Sep, 2022 | 13:06h | UTC

Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Tocilizumab as a Novel Therapy for Steroid-Dependent Polymyalgia Rheumatica – JAMA (free for a limited period)

Video Editor’s Note: Tocilizumab and Disease Activity in Patients With Polymyalgia Rheumatica Receiving Glucocorticoid Therapy – JAMA

 


RCTs | Effect of Roflumilast cream vs. vehicle cream on chronic plaque psoriasis.

22 Sep, 2022 | 13:06h | UTC

Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials – JAMA (free for a limited period)

Editorial: Roflumilast for Chronic Plaque Psoriasis – JAMA

Commentary: Study Suggests Roflumilast May Be Effective As Treatment For Plaque Psoriasis – HCPLive

 

Commentary on Twitter

 


RCT | Deucravacitinib vs. placebo and Apremilast in moderate to severe plaque psoriasis.

20 Sep, 2022 | 13:16h | UTC

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial – Journal of the American Academy of Dermatology

 


RCT | Methotrexate may increase response rates in patients with uncontrolled gout receiving Pegloticase.

19 Sep, 2022 | 12:38h | UTC

A Randomized Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT): Primary Efficacy and Safety Findings – Arthritis & Rheumatology

Commentary: Data Now Out for Pegloticase-MTX Combo Gout Treatment – MedPage Today (free registration required)

 


RCT | Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumor necrosis factor inhibitor therapy.

19 Sep, 2022 | 12:35h | UTC

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study – Annals of Rheumatic Diseases

 


Study finds a higher complication rate after acute coronary syndrome in patients with rheumatic immune‐mediated inflammatory diseases.

15 Sep, 2022 | 13:01h | UTC

Outcomes Following Acute Coronary Syndrome in Patients With and Without Rheumatic Immune‐Mediated Inflammatory Diseases – Journal of the American Heart Association

News Release: Study finds higher complication rate after heart attack in people with autoimmune disease – American Heart Association

 


M-A of randomized trials | Digital health interventions for musculoskeletal pain conditions.

14 Sep, 2022 | 13:08h | UTC

Digital Health Interventions for Musculoskeletal Pain Conditions: Systematic Review and Meta-analysis of Randomized Controlled Trials – Journal of Medical Internet Research

 


Phase 2 RCT | Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease.

6 Sep, 2022 | 14:22h | UTC

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study – The Lancet Respiratory Medicine

 

Commentary on Twitter

 


RCT | In patients with rheumatoid arthritis, Tofacitinib is associated with increased risk of infections compared to TNF inhibitors.

1 Sep, 2022 | 11:50h | UTC

Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial – Annals of Rheumatic Diseases

 

Commentary on Twitter

 


#ESCCongress | Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomized, double-blind trials.

30 Aug, 2022 | 12:16h | UTC

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials – The Lancet

News Release: Cardiovascular protection from statins greatly outweighs the risk of muscle symptoms – European Society of Cardiology

Commentary: Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration – TCTMD

 


[News release – not published yet] #ESCCongress – RCT | Allopurinol does not improve cardiovascular outcomes in ischemic heart disease patients.

29 Aug, 2022 | 12:15h | UTC

Allopurinol does not improve cardiovascular outcomes in ischaemic heart disease patients – European Society of Cardiology

Commentary:

ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention – TCTMD

No improvement with allopurinol for patients with ischemic heart disease: ALL-HEART – Cardiology Now

 


Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.

29 Aug, 2022 | 12:11h | UTC

Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK – The Lancet (free registration required)

Commentary: Population-based study: Autoimmune disorders increase risk of cardiovascular disease – MedicalXpress

 


RCT | Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis.

29 Aug, 2022 | 11:58h | UTC

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 


RCT | Olokizumab vs. Placebo or Adalimumab in rheumatoid arthritis.

25 Aug, 2022 | 12:04h | UTC

Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Novel IL-6 Blocker Matches Humira in Rheumatoid Arthritis – MedPage Today (free registration required)

 


Observational study suggests Hydroxychloroquine is associated with increased risk of cardiovascular events compared to Methotrexate in patients with heart failure.

25 Aug, 2022 | 11:56h | UTC

Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Editorial: Hydroxychloroquine: Heart-Throb No More? – Journal of the American College of Cardiology

Commentary: Caution needed with hydroxychloroquine use in older RA patients with heart failure – medwire News

 


Systematic Review | Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease.

25 Aug, 2022 | 11:55h | UTC

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider – RMD Open

Related: EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.

 


Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach.

24 Aug, 2022 | 14:09h | UTC

Management of hand osteoarthritis: from an US evidence-based medicine guideline to a European patient-centric approach – Aging Clinical and Experimental Research

Related:

Erosive hand osteoarthritis: latest findings and outlook – Nature Reviews Rheumatology

Efficacy of corticosteroids for hand osteoarthritis – a systematic review and meta-analysis of randomized controlled trials – BMC Musculoskeletal Disorders

ACR Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee

#ACR19 – Randomized Trial: Low-Dose Corticosteroids for Short Periods Effective and Safe for Hand Osteoarthritis

#ACR19 – [Not Published Yet] Randomized Trial: Methotrexate May Reduce Joint Damage Progression in Erosive Hand Osteoarthritis

Research: Hydroxychloroquine Effectiveness in Reducing Symptoms of Hand Osteoarthritis

 


Podcast | Myositis and myopathy.

24 Aug, 2022 | 14:04h | UTC

#348 Myositis and Myopathy, LIVE! – The Curbsiders

 


Systematic Review | There is insufficient evidence to recommend running shoes for preventing lower limb running injuries in adults.

23 Aug, 2022 | 13:00h | UTC

Running shoes for preventing lower limb running injuries in adults – Cochrane Library

Summary: Running shoes for preventing lower-limb running injuries in adults – Cochrane Library

 

Commentary on Twitter

 


Consensus Statement | Preoperative management of medications for rheumatologic and HIV diseases.

22 Aug, 2022 | 12:22h | UTC

Preoperative Management of Medications for Rheumatologic and HIV Diseases: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Related:

Preoperative Evaluation and Management of Patients With Select Chronic Gastrointestinal, Liver, and Renal Diseases – Mayo Clinic Proceedings

Preoperative Management of Medications for Neurologic Diseases – Mayo Clinic Proceedings

Preoperative Management of Medications for Psychiatric Diseases: Society for Perioperative Assessment and Quality Improvement Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Gastrointestinal and Pulmonary Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Endocrine, Hormonal, and Urologic Medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Opioid and Nonopioid Analgesics: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement – Mayo Clinic Proceedings

Preoperative Management of Surgical Patients Using Dietary Supplements – Mayo Clinic Proceedings

Perioperative Evaluation and Management of Endocrine Disorders – Mayo Clinic Proceedings

Preoperative Cardiac Risk Assessment – Mayo Clinic Proceedings

Preoperative Evaluation Before Noncardiac Surgery – Mayo Clinic Proceedings

Perioperative Cardiac Risk Reduction in Noncardiac Surgery – Mayo Clinic Proceedings

Examining Risk: A Systematic Review of Perioperative Cardiac Risk Prediction Indices – Mayo Clinic Proceedings

Perioperative Venous Thromboembolism Prophylaxis – Mayo Clinic Proceedings

 


RCT | Surgical reconstruction is superior to rehabilitation for patients with non-acute anterior cruciate ligament injury with persistent symptoms of instability.

22 Aug, 2022 | 12:16h | UTC

Rehabilitation versus surgical reconstruction for non-acute anterior cruciate ligament injury (ACL SNNAP): a pragmatic randomised controlled trial – The Lancet

 

Commentary on Twitter

Under a Creative Commons Attribution (CC BY 4.0) license

 


Review | Systemic lupus erythematosus and cardiovascular disease.

22 Aug, 2022 | 12:02h | UTC

Systemic lupus erythematosus and cardiovascular disease – Journal of Internal Medicine

 


M-A | Efficacy of corticosteroids for hand osteoarthritis.

19 Aug, 2022 | 16:03h | UTC

Efficacy of corticosteroids for hand osteoarthritis – a systematic review and meta-analysis of randomized controlled trials – BMC Musculoskeletal Disorders

 


Review | Autoimmune/autoinflammatory syndrome induced by adjuvants: a focus on silicone.

18 Aug, 2022 | 12:34h | UTC

Autoimmune/autoinflammatory syndrome induced by adjuvants: a focus on silicone – Clinical Rheumatology

 

Commentary on Twitter

 


Cohort Study | Racial and sex disparities in gout prevalence among adults.

16 Aug, 2022 | 13:30h | UTC

Racial and Sex Disparities in Gout Prevalence Among US Adults – JAMA Network Open

Commentary: Once the ‘Disease of Kings,’ Gout Now Reigns Through Poverty, Disparity – MedPage Today (free registration required)

 


Stay Updated in Your Specialty

No spam, just news.